Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at NYU Langone Health

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1138
Shown on this page
12
Current sort
Recently updated
Campus scope
NYU Langone Health, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within NYU Langone Health, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 385–396 of 1,138 matching trials with a site at NYU Langone Health, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

NCT05272384
Status at this site: Recruiting
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Duarte, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Recruiting Phase 3 Interventional

CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)

NCT06708299
Status at this site: Recruiting
View directory record Official record
Conditions
Recurrent Pericarditis
Interventions
CardiolRx
Drug
Lead sponsor
Cardiol Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

NCT05557045
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Anaplastic Thyroid Cancer (ATC)
Interventions
JZP815
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Denver, Colorado • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Recruiting Phase 4 Interventional

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

NCT06875960
Status at this site: Recruiting
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Interventions
BMS-986165
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Farmington, Connecticut • New York, New York • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

NCT03367741
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Recruiting Not applicable Interventional

Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

NCT06310031
Status at this site: Recruiting
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Heart Failure
Interventions
BrioVAD System, HeartMate 3
Device
Lead sponsor
BrioHealth Solutions, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
47
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Active, not recruiting Phase 1 Interventional

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395
Site status not listed — check the official record
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
Tarlatamab, Carboplatin, Etoposide, Atezolizumab, Durvalumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
9
States / cities
Los Angeles, California • Newark, Delaware • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

NCT03212274
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
51
States / cities
Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

NCT07224763
Status at this site: Recruiting
View directory record Official record
Conditions
ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
Interventions
GGTA1 KO Thymokidney
Biological
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2076
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Recruiting Not applicable Interventional

DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis

NCT05701917
Status at this site: Recruiting
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Interventions
ClotTriever System, Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
48
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Not yet recruiting Not applicable Interventional

Facial Vascularized Composite Allotransplantation: A Study Evaluating Safety, Functional Outcomes, and Patient-Reported Psychosocial Outcomes

NCT07810764
Site status not listed — check the official record
View directory record Official record
Conditions
Facial Vascularized Composite Allotransplantation, Functional Recovery
Interventions
Facial Vascularized Composite Allotransplantation (VCA)
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2037
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 2:45 AM EDT
Recruiting Not applicable Interventional

Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)

NCT07665372
Status at this site: Not yet recruiting
View directory record Official record
Conditions
HIV
Interventions
HIV D-/R+
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 24, 2026, 2:45 AM EDT

About this NYU Langone Health institution page

What this page lists
ClinicalTrials.gov records that list NYU Langone Health in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.